AbbVie's ABBV‑295 produced nearly 10% weight loss in a 76‑person Phase 1 readout, with mostly mild side effects; full data are pending conference presentation.

United Therapeutics' Phase 3 ralinepag cut clinical worsening risk by 55% and the company says the drug could be a $2B rival to J&J's Uptravi.

Federal probes into banks' AI hiring tools raise questions about bias in résumé screeners. Here’s what researchers and regulators are watching and how applicants can respond.

A St. Louis nonprofit’s white paper argues recurring drug shortages reflect structural fragility and proposes a National Fragility Index to guide purchasing and investment.

A coalition of tech researchers sued in D.C., arguing a visa policy singles out foreign experts who study social media and chills vital research.

A 1,323-pound NASA probe managed out of Maryland is expected to re-enter Earth’s atmosphere Tuesday night. Officials say the chance of debris hitting a person is extremely small.

USF’s reported research expenditures climbed to $531M — a 15% gain in two years that is drawing federal and private dollars into Tampa Bay.

A Triangle Business Journal ranking shows the region’s 25 biggest VC backers raised about $1.5B in 2025, highlighting concentrated capital and a life‑sciences tilt.

Vertex’s kidney‑disease candidate povetacicept met primary and secondary Phase 3 goals in a Week 36 interim readout, clearing an accelerated path toward an FDA filing this month.

Mayor Gina Ortiz Jones tapped a new 11‑member advisory group — led by Port San Antonio’s CEO — to pitch AI, biotech and space manufacturing to the city. The panel will advise on projects and may feed into future bond planning.

OpenAI is acquiring Promptfoo and will fold the open‑source red‑teaming toolkit into its Frontier agent platform to speed up agent security testing. Terms were not disclosed.

Adeia said it signed a multi-year IP license with AMD on March 9, 2026, resolving lawsuits over hybrid-bonding patents and opening the door to possible collaboration.

Korro Bio announced an ~$85M private placement to extend its cash runway into late 2028 after its KRRO‑110 trial fell short and staffing was cut.